Top

Published in:

01-05-2008 | Original Paper

Ethnic Variations in Chronic Liver Diseases

Authors: Nyingi Kemmer, Guy W. Neff

Published in: Digestive Diseases and Sciences | Issue 5/2008

Abstract

Chronic liver disease is a major source of morbidity and mortality in the United States today. There is little information on the interethnic variation in the clinical presentation, therapeutic responses and prognosis of individuals with liver disease. This review will discuss the ethnic variations and implications of the most common liver diseases.

Khokhar OS, Lewis JH (2007) Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci 52:1168–1176PubMedCrossRef

Trooskin SB, Navarro VJ, Winn RJ, Axelrod DJ, McNeal AS, Velez M, Herrine SK et al (2007) Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenterol 13:1074–1078PubMed

Nguyen GC, Segev DL, Thuluvath PJ (2007) Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology 45:1282–1289PubMedCrossRef

Davila JA, El-Serag HB (2006) Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 4:104–110

Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–714PubMed

Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, Margolis HS (2006) Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131:478–484PubMedCrossRef

Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS et al (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131:470–477PubMedCrossRef

Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350:2265–2271PubMedCrossRef

Shiffman ML, Mihas AA, Millwala F, Sterling RK, Luketic VA, Stravitz RT, Sanyal AJ (2007) Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 102:761–766PubMedCrossRef

10.

Kimball P, Elswick RK, Shiffman M (2001) Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 65:510–516PubMedCrossRef

11.

Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, Chang KM (2003) Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 37:590–599PubMedCrossRef

12.

Keenan ED, Rouster SD, Shire NJ, Horn PS, Sherman KE (2004) Complexity and diversity of hepatitis C virus RNA in African Americans and whites: analysis of the envelope-coding domain. J Infect Dis 190:511–514PubMedCrossRef

13.

Park VM, Mason BC, Krushkal J, Li R, Riely C, Fleckenstein J (2007) Hepatitis C hypervariable region 1: association of reduced selection pressure in African Americans with treatment failure. Dig Dis Sci (in press) DOI: 10.1007/s10620-006-9726-8

14.

Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS (2007) Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45:80–87PubMedCrossRef

15.

Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Anand BS, Brau N et al (2005) Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 100:2186–2193PubMedCrossRef

16.

Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR (2005) Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 3:604–609PubMedCrossRef

17.

Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD et al (2007) Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of US veterans. Dig Dis Sci 52:570–578PubMedCrossRef

18.

Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O et al (2006) Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 26:1119–1125PubMedCrossRef

19.

Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S et al (2004) The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40:484–490PubMedCrossRef

20.

Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, Shiffman ML (2004) A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2:469–473PubMedCrossRef

21.

Crosse K, Umeadi OG, Anania FA, Laurin J, Papadimitriou J, Drachenberg C, Howell CD (2004) Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2:463–468PubMedCrossRef

22.

Lepe R, Layden-Almer JE, Layden TJ, Cotler S (2006) Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat 13:116–120PubMedCrossRef

23.

Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A (2006) More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 101:1817–1823PubMedCrossRef

24.

Wiley TE, Brown J, Chan J (2002) Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 97:700–706PubMedCrossRef

25.

Pearlman BL (2006) Hepatitis C virus infection in African Americans. Clin Infect Dis 42:82–91PubMedCrossRef

26.

Armstrong EP, Charland SL (2004) Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin 20:671–679PubMedCrossRef

27.

Neal KR (2007) Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 56:1098–1104PubMedCrossRef

28.

Nguyen GC, Segev DL, Thuluvath PJ (2007) Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol (in press) DOI:10.1016/j.cgh.2007.04.027

29.

Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL (2005) Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 42:1406–1413PubMedCrossRef

30.

Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97–107PubMedCrossRef

31.

McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS (1999) Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 89:14–18PubMed

32.

Kramvis A, Kew MC (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 37:S9–S19PubMedCrossRef

33.

Gish RG, Gadano AC (2006) Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 13:787–798PubMedCrossRef

34.

Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W et al (2003) Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 125:444–451PubMedCrossRef

35.

Liu CJ, Kao JH, Chen DS (2005) Therapeutic implications of hepatitis B virus genotypes. Liver Int 25:1097–1107PubMedCrossRef

36.

Kao JH, Chen PJ, Lai MY, Chen DS (2000) Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554–559PubMedCrossRef

37.

Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS (2000) Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33:998–1002PubMedCrossRef

38.

Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123–129PubMedCrossRef

39.

Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W et al (2003) Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38:619–628PubMedCrossRef

40.

Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA (2005) Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41:372–379PubMedCrossRef

41.

Browning JD, Kumar KS, Saboorian MH, Thiele DL (2004) Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99:292–298PubMedCrossRef

42.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387–1395PubMedCrossRef

43.

Caldwell SH, Harris DM, Patrie JT, Hespenheide EE (2002) Is NASH underdiagnosed among African Americans? Am J Gastroenterol 97:1496–1500PubMedCrossRef

44.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T et al (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722–728PubMed

45.

Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef

46.

Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 163:427–436PubMedCrossRef

47.

Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, De Michieli F et al (2005) Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100:2438–2446PubMedCrossRef

48.

Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N (2005) Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 39:237–242PubMedCrossRef

49.

Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF et al (2005) Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54:117–121PubMedCrossRef

50.

Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA (2004) Ethnic differences in adiponectin levels. Metabolism 53:1–3PubMedCrossRef

51.

Ruhl CE, Everhart JE (2001) Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 74:295–301PubMed

52.

Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, Diehl AM et al (2005) Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 1:6–11PubMedCrossRef

53.

Ratziu V, Poynard T (2006) Assessing the outcome of nonalcoholic steatohepatitis? It’s time to get serious. Hepatology 44:802–805PubMedCrossRef

54.

Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM (2006) Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44:874–880PubMedCrossRef

55.

Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P et al (1996) Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 23:1025–1029PubMedCrossRef

56.

Becker U, Gronbaek M, Johansen D, Sorensen TI (2002) Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 35:868–875PubMedCrossRef

57.

Gronbaek M, Becker U, Johansen D, Gottschau A, Schnohr P, Hein HO, Jensen G et al (2000) Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med 133:411–419PubMed

58.

Stewart SH (2002) Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. Arch Intern Med 162:2236–2239PubMedCrossRef

59.

Stinson FS, Grant BF, Dufour MC (2001) The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 25:1181–1187PubMedCrossRef

60.

Lorenzo A, Auguet T, Vidal F, Broch M, Olona M, Gutierrez C, Lopez-Dupla M et al (2006) Polymorphisms of alcohol-metabolizing enzymes and the risk for alcoholism and alcoholic liver disease in Caucasian Spanish women. Drug Alcohol Depend 84:195–200PubMedCrossRef

61.

Zintzaras E, Stefanidis I, Santos M, Vidal F (2006) Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 43:352–361PubMedCrossRef

62.

Lim KN, Casanova RL, Boyer TD, Bruno CJ (2001) Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 96:3390–3394PubMedCrossRef

63.

Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG (2002) Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 50:713–717PubMedCrossRef

64.

D’Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR (2005) An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 25:325–330PubMedCrossRef

65.

Acton RT, Barton JC, Snively BM, McLaren CE, Adams PC, Harris EL, Speechley MR et al (2006) Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Ethn Dis 16:815–821PubMed

66.

Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW et al (2005) Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352:1769–1778PubMedCrossRef

67.

de Serres FJ (2002) Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 122:1818–1829PubMedCrossRef

68.

Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007) Population-based surveillance for acute liver failure. Am J Gastroenterol 102:1–5CrossRef

69.

Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P (2004) Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 10:1018–1023PubMedCrossRef

70.

Kronenberg F, Cushman LF, Wade CM, Kalmuss D, Chao MT (2006) Race/ethnicity and women’s use of complementary and alternative medicine in the United States: results of a national survey. Am J Public Health 96:1236–1242PubMedCrossRef

71.

Verma S, Thuluvath PJ (2007) Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol 5:408–416PubMedCrossRef

72.

Schiano TD (2003) Hepatotoxicity and complementary and alternative medicines. Clin Liver Dis 7:453–473PubMedCrossRef

73.

Neff GW, O’Brien C, Montalbano M, DeManno A, Kahn S, Safdar K, Nishida S et al (2004) Consumption of dietary supplements in a liver transplant population. Liver Transpl 10:881–885PubMedCrossRef

74.

Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM et al (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947–954PubMed

75.

Heijne WH, Stierum RH, Leeman WR, van Ommen B (2005) The introduction of toxicogenomics; potential new markers of hepatotoxicity. Cancer Biomark 1:41–57PubMed

76.

McGlynn KA, Tarone RE, El-Serag HB (2006) A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomark Prev 15:1198–1203CrossRef

77.

Kemmer N, Neff G, Secic M, Zacharias V, Kaiser T, Buell J (2007) Ethnic differences in hepatocellular carcinoma: implications for liver transplantation. Dig Dis Sci (in press) DOI: 10.1007/s10620-007-9872-7

78.

Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB (2002) Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 36:410–417PubMedCrossRef

79.

Harrison LE, Reichman T, Koneru B, Fisher A, Wilson D, Dela Torre A, Samanta A et al (2004) Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg 139:992–996PubMedCrossRef

80.

Reid AE, Resnick M, Chang Y, Buerstatte N, Weissman JS (2004) Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl 10:834–841PubMedCrossRef

81.

Nair S, Eustace J, Thuluvath PJ (2002) Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 359:287–293PubMedCrossRef

82.

Lindholm A, Welsh M, Alton C, Kahan BD (1992) Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 52:359–371PubMedCrossRef

83.

Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ et al (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24–31PubMedCrossRef

84.

Fredericks S, Holt DW, MacPhee IA (2003) The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenomics 3:291–301PubMedCrossRef

85.

Burckart GJ, Liu XI (2006) Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 28:23–30PubMedCrossRef

Title: Ethnic Variations in Chronic Liver Diseases
Authors: Nyingi Kemmer
Guy W. Neff
Publication date: 01-05-2008
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 5/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-9992-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Hepatitis-G Virus Infection in Multi-transfused Patients and Intravenous Drug Abusers: New Delhi Experience

A Role of Cell Apoptosis in Lipopolysaccharide (LPS)-induced Nonlethal Liver Injury in d-galactosamine (d-GalN)-sensitized Rats

Atypical Presentation and Etiology of Left-sided Portal Hypertension

Empiric Dilation in Non-obstructive Dysphagia

Comparative Effects of Several Therapatic Agents on Hepatic Damage Induced by Acute Experimental Pancreatitis

Mcp-1, eNOS, tPA and PAI-1 Gene Polymorphism and Correlation of Genotypes and Phenotypes in Hepatopulmonary Syndrome

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials